Status:
COMPLETED
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
Lead Sponsor:
US Department of Veterans Affairs
Collaborating Sponsors:
Oregon Health and Science University
Conditions:
Dyskinesias
Movement Disorders
Eligibility:
All Genders
21+ years
Brief Summary
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. I...
Detailed Description
Levodopa induced dyskinesia (LID) is a major problem associated with chronic use of levodopa (LD) for symptomatic treatment of Parkinson's disease (PD). LD remains our most potent therapy and nearly a...
Eligibility Criteria
Inclusion
- Clinical diagnosis of probable idiopathic Parkinson's Disease or no neurologic disease (no disease for controls only)
- At least 21 years of age
- Mini Mental Status Exam Score\>=25
Exclusion
- Evidence of psychosis (hallucinations or delusions) by history
- Any unstable medical condition
- Currently using dopamine blocking medication
- Currently taking anticoagulants or MAO inhibitors
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00467597
Start Date
April 1 2006
End Date
October 1 2013
Last Update
November 26 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, Portland
Portland, Oregon, United States, 97201